BioSpace News Archive

Drug Development

Alzheon Launches IPO to Fund Alzheimer’s Drug

Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.

March 19, 2018
·
2 min read
·
Mark Terry
Drug Development

Regeneron’s Eylea Shows Promising Data for Diabetic Retinopathy

Regeneron Pharmaceuticals announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

March 19, 2018
·
2 min read
·
Mark Terry
Drug Development

Heron Therapeutics Soars on Positive Phase III Results

Heron Therapeutics said its late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain – a significant point as the nation is in the grip of an opioid epidemic.

March 19, 2018
·
3 min read
·
Alex Keown
Bio NC

Study Reveals Huge Potential for mRNA Drug Targets

Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space.

March 19, 2018
·
2 min read
·
Alex Keown
Drug Development

Cidara Touts Positive Phase II Antifungal Data

Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year.

March 19, 2018
·
2 min read
·
Alex Keown
Biotech Bay

6 Biotech Companies with Upside Potential

Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.

March 19, 2018
·
3 min read
·
Mark Terry
New Study Indicates DNA Plays Role in Gender Identity

In the world of politics and civil rights, the ideas of gender and transgender have been a hot-button issue. But a new study suggests that transgender people may have a genetic disposition that influences their identity.

March 19, 2018
·
2 min read
·
Alex Keown
Business

Denali Therapeutics Adds $155 Million from Takeda

Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.

March 19, 2018
·
3 min read
·
Mark Terry
Business

ExThera Medical Announces Creation of European Subsidiary

ExThera Medical Corporation announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary.

March 19, 2018
·
2 min read
Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing Round

Elthera is pleased to announce that it has demonstrated efficacy of its proprietary antibodies in tumor bearing animals.

March 19, 2018
·
2 min read